Implementing Prevention of Venous Thromboembolism for Ambulatory Patients with Cancer (PREVenT-APC)
对门诊癌症患者实施静脉血栓栓塞预防 (PREVenT-APC)
基本信息
- 批准号:10659200
- 负责人:
- 金额:$ 16.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-15 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdherenceAdoptionAmericanAnticoagulationApplied SkillsBehavior TherapyBehavioralCancer PatientCaringCause of DeathClinicClinicalClinical Practice GuidelineClinical Trials DesignCommunitiesConsolidated Framework for Implementation ResearchDataEducationEffectivenessEventFoundationsFundingFutureGoalsGuidelinesHealth Care CostsHematologyHemorrhageHemostatic functionHigh-Risk CancerHospitalizationIncidenceInternationalK-Series Research Career ProgramsKnowledgeLogicMalignant NeoplasmsMeasuresMentored Patient-Oriented Research Career Development AwardMentorsMeta-AnalysisMethodsModelingNational Comprehensive Cancer NetworkOncologistOncologyOutcomePatient CarePatient-Focused OutcomesPatientsPhysiciansPreventionProctor frameworkProphylactic treatmentRandomized, Controlled TrialsRecommendationResearchResearch MethodologyResearch PersonnelRiskRisk AssessmentScientistSiteSocietiesSurveysSystemTestingThrombosisWorkcareercareer developmentchemotherapyclinical practicecohortcontextual factorsdesigndissemination scienceeffectiveness evaluationevidence baseevidence based guidelineshigh riskimplementation evaluationimplementation outcomesimplementation scienceimplementation strategyimprovedimproved outcomemalignant stomach neoplasmmedical specialtiesmultimodalitypancreatic cancer patientspreventprophylacticrandomized trialrisk stratificationscreeningtooltreatment as usualtumor progressionuptakeusabilityvenous thromboembolism
项目摘要
PROJECT SUMMARY
Background: Venous thromboembolism (VTE) is one of the most common causes of death in cancer
patients. Guidelines recommend the use of VTE risk-stratification to identify ambulatory patients with
cancer at high-risk of VTE who may benefit from primary VTE prevention with prophylactic
anticoagulation. However, our preliminary data suggest that VTE risk assessment and primary
prophylaxis are substantially underused.
Aims and Methods: The overall objective of this project is to develop a feasible, effective, and
sustainable implementation strategy to promote the uptake into clinical practice of evidence-based
guidelines for VTE prevention in patients with cancer. The Specific Aims of this proposal are to:
Aim 1: Conduct formative research to develop an implementation strategy (PREVenT-APC)
promoting the uptake in clinical practice of a guideline-recommended, risk-based approach
to primary VTE prevention for ambulatory patients with cancer;
Aim 2: Using a randomized trial, assess effectiveness of the refined PREVenT-APC strategy as
compared with usual care, to start and maintain thromboprophylaxis for identified high-risk
patients with cancer; and
Aim 3: Explore implementation outcomes and the contextual factors associated with variability in
adoption, fidelity, effectiveness, and acceptability of the PREVenT-APC implementation
strategy.
To carry out the study, I will develop the PREVenT-APC strategy and conduct usability testing to refine
the strategy (Aim 1); test the PREVenT-APC strategy via a randomized trial (Aim 2); and, using mixed
methods, evaluate additional implementation outcomes, and explore variability in outcomes of the
PREVenT-APC strategy (Aim 3).
Career Development and Future Work: Through the objectives of the K23 Mentored Career
Development Award, I will acquire advanced knowledge and apply skills in mixed method research,
behavioral intervention clinical trial design, and dissemination and implementation science, which will
further my goal of becoming an independent physician scientist with expertise in developing,
implementing, and evaluating strategies to improve cross-specialty hematology care. The study findings
will serve as a foundation for future R-level proposals to tailor and test adaptations and dissemination of
the PREVenT-APC implementation strategy in different settings. Ultimately, the long-term goal of the
proposed research is to reduce VTE and improve outcomes for patients with cancer.
项目摘要
背景:静脉血栓栓塞(VTE)是癌症最常见的死亡原因之一
患者指南建议使用VTE风险分层来识别患有以下疾病的非卧床患者:
可能受益于预防性一级VTE预防的VTE高危癌症患者
抗凝然而,我们的初步数据表明,静脉血栓栓塞风险评估和主要
预防措施基本上没有得到充分利用。
目的和方法:本项目的总体目标是制定一个可行的,有效的,
可持续实施战略,以促进将循证医学纳入临床实践
癌症患者静脉血栓栓塞预防指南。该提案的具体目标是:
目标1:开展形成性研究,以制定执行战略(PREVent-APC)
促进在临床实践中采用指南推荐的基于风险的方法
对非卧床癌症患者进行一级静脉血栓栓塞预防;
目的2:使用随机试验,评估改进的PREVent-APC策略的有效性,
与常规治疗相比,对于已确定的高风险患者,
癌症患者;以及
目标3:探索实施结果和与变异性相关的背景因素,
PREVent-APC实施的采用、忠实性、有效性和可接受性
战略
为了进行这项研究,我将制定预防-APC策略,并进行可用性测试,以完善
策略(目标1);通过随机试验测试PREVent-APC策略(目标2);以及,使用混合
方法,评估其他实施成果,并探讨
预防APC战略(目标3)。
职业发展和未来的工作:通过K23指导职业生涯的目标
发展奖,我将获得先进的知识和应用混合方法研究的技能,
行为干预临床试验设计,传播和实施科学,这将
进一步我的目标是成为一个独立的医生科学家与专业知识的发展,
实施和评估策略,以改善跨专业血液学护理。研究结果
将作为未来R级提案的基础,以调整和测试
不同环境下的预防艾滋病毒/艾滋病方案执行战略。最终,
拟议的研究是减少静脉血栓栓塞和改善癌症患者的预后。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karlyn Martin其他文献
Karlyn Martin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karlyn Martin', 18)}}的其他基金
Implementing Prevention of Venous Thromboembolism for Ambulatory Patients with Cancer (PREVenT-APC)
对门诊癌症患者实施静脉血栓栓塞预防 (PREVenT-APC)
- 批准号:
10448949 - 财政年份:2022
- 资助金额:
$ 16.7万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 16.7万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 16.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 16.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 16.7万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 16.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 16.7万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 16.7万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 16.7万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 16.7万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 16.7万 - 项目类别:
Standard Grant